Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Marta, Krejci"'
Autor:
Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/5aea7f2816d842e89d6116072aa074df
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
Publikováno v:
Neoplasma. 69:1008-1018
Chimeric antigen receptor (CAR)-T cells are a new treatment modality in various hematological malignancies, including relapsed/refractory multiple myeloma (RRMM). RRMM patients have a poor prognosis, and their treatment options are limited. Currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2256c384bb6ac64d6fbeb8734d5f275b
https://doi.org/10.4149/neo_2022_220504n477
https://doi.org/10.4149/neo_2022_220504n477
Autor:
Holger W. Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout, Didier Blaise, Nigel H. Russell, Jane F. Apperley, David Pohlreich, Paul V. Browne, Guido Kobbe, Cecilia Isaksson, Stig Lenhoff, Christof Scheid, Cyrille Touzeau, Esa Jantunen, Achilles Anagnostopoulos, Ibrahim Yakoub-Agha, Alina Tanase, Nicolaas Schaap, Wieslaw Wiktor-Jedrzejczak, Marta Krejci, Stefan O. Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxic
Externí odkaz:
https://doaj.org/article/f705fa443a5b491689e9661527014272
Autor:
Louise de Swart, Chloé Reiniers, Timothy Bagguley, Corine van Marrewijk, David Bowen, Eva Hellström-Lindberg, Aurelia Tatic, Argiris Symeonidis, Gerwin Huls, Jaroslav Cermak, Arjan A. van de Loosdrecht, Hege Garelius, Dominic Culligan, Mac Macheta, Michail Spanoudakis, Panagiotis Panagiotidis, Marta Krejci, Nicole Blijlevens, Saskia Langemeijer, Jackie Droste, Dorine W. Swinkels, Alex Smith, Theo de Witte
Publikováno v:
Haematologica, Vol 103, Iss 1 (2018)
Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients with myelodysplastic syndromes. We hypothesized that patients develop oxidant-mediated tissue injury through the formation of toxic iron species, cau
Externí odkaz:
https://doaj.org/article/b1a31300b6a84686a4b8302f807f6d32
Autor:
Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova, Roman Hajek
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0137294 (2015)
Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extr
Externí odkaz:
https://doaj.org/article/1c18f8435a574f45a2322070f78e88ad
Autor:
Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Ivan Spicka, Jiri Jarkovsky, Marta Krejci, Jaroslav Bacovsky, Jakub Radocha, Jan Straub, Petr Kessler, Marek Wrobel, Lenka Walterova, Michal Sykora, Jarmila Obernauerova, Lucie Brozova, Evzen Gregora, Dagmar Adamova, Jaromir Gumulec, Zdenek Adam, Vlastimil Scudla, Roman Hajek, Czech Myeloma Group
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0123866 (2015)
OBJECTIVE:Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) pat
Externí odkaz:
https://doaj.org/article/781e01a2fb62439984783e51c9bbd51c
Autor:
Ludek Pour, Sabina Sevcikova, Henrieta Greslikova, Renata Kupska, Petra Majkova, Lenka Zahradova, Viera Sandecka, Zdenek Adam, Marta Krejci, Petr Kuglik, Roman Hajek
Publikováno v:
Haematologica, Vol 99, Iss 2 (2014)
Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analy
Externí odkaz:
https://doaj.org/article/0766d57b3426413996d8c3f579902bc9
Autor:
Blanka, Robesova, Marie, Drncova, Adam, Folta, Marta, Krejci, Frantisek, Folber, Zuzana, Sustkova, Jiri, Mayer, Ivana, Jeziskova
Publikováno v:
Bone marrow transplantation. 55(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d8332568fdb0845cf660631f0ee01f8b
https://pubmed.ncbi.nlm.nih.gov/32388533
https://pubmed.ncbi.nlm.nih.gov/32388533
Publikováno v:
American Journal of Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=r3c4b2081b22::d07362a3c73bda264c9174348ded18c7
Autor:
Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Ivan Spicka, Jiri Jarkovsky, Marta Krejci, Jaroslav Bacovsky, Jakub Radocha, Jan Straub, Petr Kessler, Marek Wrobel, Lenka Walterova, Michal Sykora, Jarmila Obernauerova, Lucie Brozova, Evzen Gregora, Dagmar Adamova, Jaromir Gumulec, Zdenek Adam, Vlastimil Scudla, Roman Hajek, Czech Myeloma Group
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 4, p e0123866 (2015)
PLoS ONE, Vol 10, Iss 4, p e0123866 (2015)
OBJECTIVE:Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f7dd87456382844b19f44d0dcd0239
https://pubmed.ncbi.nlm.nih.gov/25875484
https://pubmed.ncbi.nlm.nih.gov/25875484